Le Lézard
Classified in: Health
Subject: ACC

Number of Shares and Votes in Oncopeptides


STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company's incentive programs.

Through the exercise of warrants under the company's incentive programs, the number of outstanding shares and votes have increased by 21,266 from 61,478,417 to 61,499,683. The share capital has increased by approximately SEK 2,363 from SEK 6,830,935 to SEK 6,833,298.

The information in the press release is information that Oncopeptides is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons above, on June 30, 2020 at 14.00 (CEST).

About Oncopeptides

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class aminopeptidase-targeting peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological malignancy multiple myeloma and is currently being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides' headquarters is in Stockholm, Sweden with its U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

For more information visit www.oncopeptides.com.

For further information, please contact:
Jakob Lindberg, CEO of Oncopeptides
E-mail: [email protected]
Telephone: +46 8 615 20 40

Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: [email protected]
Cell phone: +46 70 853 72 92

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/oncopeptides-ab/r/number-of-shares-and-votes-in-oncopeptides,c3145109

The following files are available for download:

https://mb.cision.com/Main/15404/3145109/1272096.pdf

Press release - Number of shares and votes in Oncopeptides

 

SOURCE Oncopeptides AB


These press releases may also interest you

at 15:14
Cymbiotika, a trailblazer in health and wellness, is thrilled to announce the launch of its new pet line, meticulously crafted to enhance the health and vitality of beloved pets. The new line includes four revolutionary products: Probiotic+, Calm,...

at 15:00
TELUS Health revealed today the results of its 2024 Drug Data Trends and National Benchmarks Report at its 20th annual TELUS Health Conference, running today and April 30. Diabetes medications remain the leading drug category for eligible private...

at 14:45
With safe seated mammography trending in the U.S., the Samuel U. Rodgers Health Center (Sam Rodgers) reports its use of the Danish made VELA Mammography Chair has provided significant physical benefits for patients, health benefits for mammographers,...

at 14:35
MD Logic Health® is excited to announce a groundbreaking partnership with renowned Nutritional Therapy Practitioner, Liz Wolfe, to launch an innovative new supplement, Daily Aminos+. This collaboration combines MD Logic Health®'s expertise in...

at 14:34
Last week, the Internal Revenue Service (IRS) issued a groundbreaking announcement on the tax treatment of work-life referral services provided to employees under an employer's work-life referral program. This development marks a significant...

at 14:30
Summer Health, a digital health company offering 24/7 pediatric support to parents, announced $11.65M in Series A Funding, co-led by new investor 7wire Ventures and returning investor Lux Capital. Returning investors Sequoia Capital, Metrodora...



News published on and distributed by: